MedTrace Logo

Continuous Glucose Monitoring in Dialysis Patients to Overcome Dysglycemia Trial

NCT05509881 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2024-02-28

No results posted yet for this study

Summary

This randomized controlled trial will investigate whether use of continuous glucose monitoring (CGM) vs. usual care with self-monitored blood glucose 1) enhances glycemic control, 2) reduces hypoglycemia risk, and 3) improves quality of life, diabetes distress, and fear of hypoglycemia in hemodialysis patients with diabetes mellitus.

Conditions

  • Hemodialysis
  • Diabete Mellitus
  • Continuous Glucose Monitoring

Interventions

DEVICE

Continuous glucose monitoring (CGM)

Patients in the CGM arm will undergo continuous real-time "unblinded" CGM using Dexcom CGM devices.

DEVICE

Usual care (Self-monitored blood glucose)

Patients in the usual care arm will conduct self-monitored blood glucose at least 4 times/day.

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • University of California, Irvine

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-12
Primary Completion
2026-01-31
Completion
2026-01-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05509881 on ClinicalTrials.gov